• Eli Lilly (NYSE:LLY) has entered a $1 billion AI-focused drug discovery partnership with Nvidia, aimed at using advanced computing to support pharmaceutical R&D.
• The company received a positive opinion from the EMA for Olumiant in adolescents with severe alopecia areata.
• Phase 3 results for its oral GLP-1 candidate orforglipron were reported as promising, adding to its metabolic pipeline.
• The FDA approved a new label for Zepbound, broadening Eli Lilly's weight loss therapy offering.

For investors tracking Eli Lilly at a share price of $1,003.57, these updates follow a mixed period for the stock. NYSE:LLY is down 2.5% over the past week, 3.9% over the past month, and 7.1% year to date, while showing an 8.7% gain over the past year and a five-year return of more than four times.

The combination of a $1 billion AI partnership and progress across immunology, diabetes, and obesity treatments places Eli Lilly at the intersection of large-scale computing and established drug development. Investors may monitor how quickly these AI initiatives affect pipeline productivity and how the expanding obesity and metabolic portfolio influences longer-term interest in the stock.

Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly.

Quick Assessment

• ✅ Price vs Analyst Target: At US$1,003.57 versus a consensus target of about US$1,214, the price sits roughly 17% below where analysts expect it.
• ✅ Simply Wall St Valuation: Simply Wall St views Eli Lilly as trading about 30.5% below its estimated fair value.
• ❌ Recent Momentum: The 30 day return is about 3.9% lower, so short term performance has been weak.

There is only one way to know the right time to buy, sell or hold Eli Lilly. Head to Simply Wall St's company report for the latest analysis of Eli Lilly's fair value.

Key Considerations

• 📊 The US$1b AI partnership with Nvidia and fresh regulatory wins support the case that Lilly is investing heavily in future drug discovery and its pipeline.
• 📊 Watch how AI related R&D spend, obesity and metabolic drug uptake, and earnings vs the current 43.4x P/E develop over coming updates.
• ⚠️ The company has a high level of debt and a high level of non cash earnings, so balance sheet strength and earnings quality are key items to monitor.

Dig Deeper

For the full picture, including more risks and rewards, check out the complete Eli Lilly analysis. Alternatively, you can check out the community page for Eli Lilly to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.